What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addr...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: McGovern, A, Dennis, J, Shields, B, Hattersley, A, Pearson, E, Jones, A, Mastermind Consortium
Beste egile batzuk: Farmer, A
Formatua: Journal article
Hizkuntza:English
Argitaratua: BioMed Central 2019